PROPRANOLOL
Common Migraine
Norwegian University of Science and TechnologySmall moleculePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Common Migraine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 4 | BBB |
Dihydroergotamine mesylate Satsuma Pharmaceuticals, Inc. | Phase 3 | BBB |
Rimegepant University of South Florida | Phase 4 | BB |
METOCLOPRAMIDE Assistance Publique - Hôpitaux de Paris | Phase 4 | BB |
DEXKETOPROFEN Kecioren Education and Training Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PROPRANOLOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →